Latest Breaking News On - Elran haber - Page 1 : comparemela.com

LBP-immunotherapy could benefit oncology patients

Evogene : Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF.

Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit

REHOVOT, Israel, Jan. 23, 2024 /PRNewswire/ Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. ,.

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica s microbiome-based immuno-oncology drug, BMC128 REHOVOT, Israel, Jan. 17, 2024 /PRNewswire/ .

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024 - Evogene

Rehovot, Israel - - Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. , is gearing up for participation in.